Durata shares jump following positive FDA AdComm meeting

Durata Therapeutics (DRTX) soars 9.5% premarket after an FDA advisory panel unanimously recommended approval of the company's Dalvance antibiotic for acute bacterial skin conditions.

"It's a highly effective drug, as demonstrated in the trial," said Thomas Moore, a clinical professor of medicine at the University of Kansas, who was on the panel.

The committee also voted to recommend the authorization of Cubist Pharmaceuticals' Sivextro, another antibiotic for skin problems.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs